Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,022

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

April 30, 2027

Conditions
Cardiac SurgeryVasoplegia
Interventions
DRUG

Angiotensin II

Intravenous infusion through a central line according to the patient's situation. Once an infusion is established, the dose will be titrated as frequently as every 5 minutes, as needed, depending on the patient's condition and target MAP.

DRUG

Noradrenalin

Intravenous infusion through a central line according to the patient's situation. Once an infusion is established, the dose will be titrated as frequently as every 5 minutes, as needed, depending on the patient's condition and target MAP.

Trial Locations (4)

13353

RECRUITING

Deutsches Herzzentrum der Charité, Berlin

49149

RECRUITING

University Hospital Münster, Münster

53127

RECRUITING

University Hospital Bonn, Bonn

55131

RECRUITING

University Medical Center Mainz, Mainz

Sponsors
All Listed Sponsors
collaborator

German Research Foundation

OTHER

lead

Universität Münster

OTHER